Biomimetic oxygen delivery nanoparticles for enhancing photodynamic therapy in triple-negative breast cancer

• Published in: Journal of nanobiotechnology 2021-03, Vol.19 (1), p.81-14, Article 81
• Main Authors: Fang, Hanyi, Gai, Yongkang, Wang, Sheng, Liu, Qingyao, Zhang, Xiao, Ye, Min, Tan, Jianling, Long, Yu, Wang, Kuanyin, Zhang, Yongxue, Lan, Xiaoli
• Format: Article
• Language: English
• Subjects: Analysis; Animals; Biocompatibility; Biomimetics; Biomimetics - methods; Blood; Breast - diagnostic imaging; Breast - pathology; Breast cancer; Cancer; Cancer cell membranes; Cancer therapies; Care and treatment; Cell Line, Tumor; Cell membranes; Complications and side effects; Cytotoxicity; Drug delivery systems; Drug resistance; Drugs; Evaluation; FDA approval; Female; Fluorescence; Homology; Hypoxia; Immunofluorescence; Injection; Lasers; Medical imaging; Metastases; Mice; Mice, Inbred BALB C; Molecular Probe Techniques; Nanoparticles; Nanoparticles - therapeutic use; Nanoprobes; Optical Imaging - methods; Oxygen; Oxygen delivery; Patient outcomes; Perfluorocarbons; Photochemotherapy; Photochemotherapy - methods; Photodynamic therapy; Photosensitizing Agents - therapeutic use; Positron emission; Positron emission tomography; Tomography; Triple Negative Breast Neoplasms - diagnostic imaging; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - pathology; Triple Negative Breast Neoplasms - radiotherapy; Triple-negative breast cancer; Tumor Microenvironment; Tumors; Vehicles; Windows (intervals); Xenograft Model Antitumor Assays; Xenografts; Xenotransplantation
• ISSN: 1477-3155; 1477-3155
• DOI: 10.1186/s12951-021-00827-2

Triple-negative breast cancer (TNBC) is a kind of aggressive breast cancer with a high rate of metastasis, poor overall survival time, and a low response to targeted therapies. To improve the therapeutic efficacy and overcome the drug resistance of TNBC treatments, here we developed the cancer cell membrane-coated oxygen delivery nanoprobe, CCm-HSA-ICG-PFTBA, which can improve the hypoxia at tumor sites and enhance the therapeutic efficacy of the photodynamic therapy (PDT), resulting in relieving the tumor growth in TNBC xenografts. The size of the CCm-HSA-ICG-PFTBA was 131.3 ± 1.08 nm. The in vitro O and ROS concentrations of the CCm-HSA-ICG-PFTBA group were both significantly higher than those of the other groups (P